ML-141
new
featured

We are open as normal during COVID-19 pandemic. Order online, same day shipping out from North Carolina, USA

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 530539

CAS#: 71203-35-5

Description: ML-141, also known as CID2950007, is a Cdc42 inhibitor (EC50 = 2.1 µM).


Price and Availability

Size Price Shipping out time Quantity
100mg USD 450 2 Weeks
200mg USD 750 2 Weeks
500mg USD 1450 2 Weeks
1g USD 2450 2 Weeks
2g USD 3850 2 Weeks
5g USD 5750 2 Weeks
Inquire bulk and customized quantity

Pricing updated 2020-10-27. Prices are subject to change without notice.

ML-141, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 530539
Name: ML-141
CAS#: 71203-35-5
Chemical Formula: C22H21N3O3S
Exact Mass: 407.1304
Molecular Weight: 407.488
Elemental Analysis: C, 64.85; H, 5.19; N, 10.31; O, 11.78; S, 7.87


Synonym: ML-141; ML 141; ML141; CID2950007; CID-2950007; CID 2950007.

IUPAC/Chemical Name: 4-[4,5-dihydro-5-(4-methoxyphenyl)-3-phenyl-1H-pyrazol-1-yl]-benzenesulfonamide

InChi Key: QBNZBMVRFYREHK-UHFFFAOYSA-N

InChi Code: InChI=1S/C22H21N3O3S/c1-28-19-11-7-17(8-12-19)22-15-21(16-5-3-2-4-6-16)24-25(22)18-9-13-20(14-10-18)29(23,26)27/h2-14,22H,15H2,1H3,(H2,23,26,27)

SMILES Code: O=S(C1=CC=C(N2N=C(C3=CC=CC=C3)CC2C4=CC=C(OC)C=C4)C=C1)(N)=O


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:
2934.99.9001


References

1: Shen J, Wang R, He Z, Huang H, He X, Zhou J, Yan Y, Shen S, Shao X, Shen X, Weng C, Lin W, Chen J. NMDA receptors participate in the progression of diabetic kidney disease by decreasing Cdc42-GTP activation in podocytes. J Pathol. 2016 Oct;240(2):149-60. doi: 10.1002/path.4764. PubMed PMID: 27338016.

2: Zhan Y, Liang X, Li L, Wang B, Ding F, Li Y, Wang X, Zhan Q, Liu Z. MicroRNA-548j functions as a metastasis promoter in human breast cancer by targeting Tensin1. Mol Oncol. 2016 Jun;10(6):838-49. doi: 10.1016/j.molonc.2016.02.002. PubMed PMID: 26949125.

3: Oprea TI, Sklar LA, Agola JO, Guo Y, Silberberg M, Roxby J, Vestling A, Romero E, Surviladze Z, Murray-Krezan C, Waller A, Ursu O, Hudson LG, Wandinger-Ness A. Novel Activities of Select NSAID R-Enantiomers against Rac1 and Cdc42 GTPases. PLoS One. 2015 Nov 11;10(11):e0142182. doi: 10.1371/journal.pone.0142182. PubMed PMID: 26558612; PubMed Central PMCID: PMC4641600.

4: Guo Y, Kenney SR, Muller CY, Adams S, Rutledge T, Romero E, Murray-Krezan C, Prekeris R, Sklar LA, Hudson LG, Wandinger-Ness A. R-Ketorolac Targets Cdc42 and Rac1 and Alters Ovarian Cancer Cell Behaviors Critical for Invasion and Metastasis. Mol Cancer Ther. 2015 Oct;14(10):2215-27. doi: 10.1158/1535-7163.MCT-15-0419. PubMed PMID: 26206334; PubMed Central PMCID: PMC4596774.

5: Cheng SL, Ramachandran B, Behrmann A, Shao JS, Mead M, Smith C, Krchma K, Bello Arredondo Y, Kovacs A, Kapoor K, Brill LM, Perera R, Williams BO, Towler DA. Vascular smooth muscle LRP6 limits arteriosclerotic calcification in diabetic LDLR-/- mice by restraining noncanonical Wnt signals. Circ Res. 2015 Jul 3;117(2):142-56. doi: 10.1161/CIRCRESAHA.117.306712. PubMed PMID: 26034040; PubMed Central PMCID: PMC4490945.

6: Ferru-Clément R, Fresquet F, Norez C, Métayé T, Becq F, Kitzis A, Thoreau V. Involvement of the Cdc42 pathway in CFTR post-translational turnover and in its plasma membrane stability in airway epithelial cells. PLoS One. 2015 Mar 13;10(3):e0118943. doi: 10.1371/journal.pone.0118943. PubMed PMID: 25768293; PubMed Central PMCID: PMC4359135.

7: Zhang Y, Liu J, Luan G, Wang X. Inhibition of the small GTPase Cdc42 in regulation of epileptic-seizure in rats. Neuroscience. 2015 Mar 19;289:381-91. doi: 10.1016/j.neuroscience.2014.12.059. PubMed PMID: 25595978.

8: Hsu CR, Pan YJ, Liu JY, Chen CT, Lin TL, Wang JT. Klebsiella pneumoniae translocates across the intestinal epithelium via Rho GTPase- and phosphatidylinositol 3-kinase/Akt-dependent cell invasion. Infect Immun. 2015 Feb;83(2):769-79. doi: 10.1128/IAI.02345-14. PubMed PMID: 25452552; PubMed Central PMCID: PMC4294243.

9: Kumar A, Al-Sammarraie N, DiPette DJ, Singh US. Metformin impairs Rho GTPase signaling to induce apoptosis in neuroblastoma cells and inhibits growth of tumors in the xenograft mouse model of neuroblastoma. Oncotarget. 2014 Nov 30;5(22):11709-22. PubMed PMID: 25365944; PubMed Central PMCID: PMC4294363.

10: Antolín AA, Mestres J. Distant polypharmacology among MLP chemical probes. ACS Chem Biol. 2015 Feb 20;10(2):395-400. doi: 10.1021/cb500393m. PubMed PMID: 25365788.

11: Chen C, Song X, Ma S, Wang X, Xu J, Zhang H, Wu Q, Zhao K, Cao J, Qiao J, Sun X, Li D, Zeng L, Li Z, Xu K. Cdc42 inhibitor ML141 enhances G-CSF-induced hematopoietic stem and progenitor cell mobilization. Int J Hematol. 2015 Jan;101(1):5-12. doi: 10.1007/s12185-014-1690-z. PubMed PMID: 25315193.

12: Weinberg MS, Nicolson S, Bhatt AP, McLendon M, Li C, Samulski RJ. Recombinant adeno-associated virus utilizes cell-specific infectious entry mechanisms. J Virol. 2014 Nov;88(21):12472-84. doi: 10.1128/JVI.01971-14. PubMed PMID: 25142580; PubMed Central PMCID: PMC4248914.

13: Hanin G, Shenhar-Tsarfaty S, Yayon N, Yau YH, Bennett ER, Sklan EH, Rao DC, Rankinen T, Bouchard C, Geifman-Shochat S, Shifman S, Greenberg DS, Soreq H. Competing targets of microRNA-608 affect anxiety and hypertension. Hum Mol Genet. 2014 Sep 1;23(17):4569-80. doi: 10.1093/hmg/ddu170. Erratum in: Hum Mol Genet. 2014 Dec 15;23(24):6694. Hoe, Yau Yin [corrected to Yau, Yin Hoe]. PubMed PMID: 24722204; PubMed Central PMCID: PMC4119407.

14: McNary SM, Athanasiou KA, Reddi AH. Transforming growth factor β-induced superficial zone protein accumulation in the surface zone of articular cartilage is dependent on the cytoskeleton. Tissue Eng Part A. 2014 Mar;20(5-6):921-9. doi: 10.1089/ten.TEA.2013.0043. PubMed PMID: 24116978; PubMed Central PMCID: PMC3938930.

15: Chen HY, Yang YM, Stevens BM, Noble M. Inhibition of redox/Fyn/c-Cbl pathway function by Cdc42 controls tumour initiation capacity and tamoxifen sensitivity in basal-like breast cancer cells. EMBO Mol Med. 2013 May;5(5):723-36. doi: 10.1002/emmm.201202140. PubMed PMID: 23606532; PubMed Central PMCID: PMC3662315.

16: Surviladze Z, Waller A, Strouse JJ, Bologa C, Ursu O, Salas V, Parkinson JF, Phillips GK, Romero E, Wandinger-Ness A, Sklar LA, Schroeder C, Simpson D, Nöth J, Wang J, Golden J, Aubé J. A Potent and Selective Inhibitor of Cdc42 GTPase. 2010 Feb 27 [updated 2010 Dec 16]. Probe Reports from the NIH Molecular Libraries Program [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2010-. Available from http://www.ncbi.nlm.nih.gov/books/NBK51965/ PubMed PMID: 21433396.